Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.37 |
| ▸ | RET | P07949 | 3/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.37 |
| ▸ | AURKA | O14965 | 2/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | PAK4 | O96013 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.37 |
| ▸ | FLT1 | P17948 | 2/20 | 0.37 |
| ▸ | LTK | P29376 | 2/20 | 0.37 |
| ▸ | GRK5 | P34947 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.37 |
| ▸ | CDK8 | P49336 | 2/20 | 0.37 |
| ▸ | CLK2 | P49760 | 2/20 | 0.37 |
| ▸ | CDK7 | P50613 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29806235 | 1.00 | JAK2 (0.37) | JAK2RETDYRK1ALRRK2DYRK1B | |
| SCHEMBL30242908 | 0.77 | GRM4 (0.32) | JAK2RETDYRK1ALRRK2DYRK1B | |
| SCHEMBL14685108 | 0.77 | GRM4 (0.32) | JAK2RETDYRK1ALRRK2DYRK1B | |
| SCHEMBL12831912 | 0.77 | DYRK1A (0.35) | JAK2RETDYRK1ALRRK2DYRK1B | |
| SCHEMBL1593072 | 0.77 | ADORA2A (0.33) | JAK2RETDYRK1ALRRK2DYRK1B | |
| SCHEMBL30370204 | 0.77 | JAK2 (0.39) | JAK2RETDYRK1ALRRK2DYRK1B | |
| SCHEMBL22582235 | 0.77 | JAK2 (0.39) | JAK2RETDYRK1ALRRK2DYRK1B | |
| SCHEMBL18921901 | 0.77 | CDK9 (0.35) | JAK2RETDYRK1ALRRK2DYRK1B | |
| SCHEMBL1496216 | 0.74 | PDPK1 (0.43) | RETLRRK2MAP4K4CDK8CDK9 | |
| SCHEMBL23107943 | 0.73 | RET (0.31) | RETLRRK2PI4KAXDHPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-15 | — | — | US | disclosed |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| EP-4079726-A1 | NOVEL PYRIMIDIN DERIVATIVE AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2022-10-26 | — | — | EP | disclosed |
| CN-114829344-A | Novel pyrimidine derivative and use thereof | 韩国化学研究院 | 2022-07-29 | — | — | CN | disclosed |
| US-20220144827-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2022-05-12 | — | — | US | disclosed |
| WO-2021125803-A1 | NOVEL PYRIMIDIN DERIVATIVE AND USE THEREOF | 한국화학연구원 | 2021-06-24 | — | — | WO | disclosed |
| US-8394795-B2 | Pyrazole [3, 4-B] pyridine Raf inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2265610-B1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-04-21 | — | — | US | disclosed |
| EP-2265610-A1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111279-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | JAK2 982/4885RET 1148/4885DYRK1A 775/4885 |
| US-20220144827-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | GRK6, GRK3, ERBB2 | JAK2 382/4885RET 44/4885DYRK1A 953/4885 |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | BRAF, RAF1, ARAF | JAK2 1269/4885RET 72/4885DYRK1A 626/4885 |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | JAK2 982/4885RET 1148/4885DYRK1A 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.